Drug Database
ET

etanercept (Qiangke)

✓ Approved

Shanghai Celgen · TNF · Recombinant Proteins

What is etanercept?

etanercept is a recombinant proteins developed by Shanghai Celgen. It is approved for therapeutic indications via injectable (others) or intraarticular injection or intravenous (iv) or subcutaneous injection.

Drug Profile

Brand NamesQiangke
CompanyShanghai Celgen
Drug ClassRecombinant Proteins
Molecular TargetTNF
RouteInjectable (Others), Intraarticular Injection, Intravenous (IV), Subcutaneous Injection
StatusApproved
Sources: ClinicalTrials.gov, Shanghai Celgen

Mechanism of Action

Molecular Targets

etanercept acts on 1 molecular target:

TNFtumor necrosis factor (TNFA, TNF-alpha)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

etanercept is developed for 5 unique indications across 2 therapeutic areas.

Therapeutic AreaConditionPhase
Musculoskeletal and connective tissue disordersAnkylosing spondylitis✓ Approved
Skin and subcutaneous tissue disordersPsoriasis✓ Approved
Musculoskeletal and connective tissue disordersPsoriatic arthropathy✓ Approved
Musculoskeletal and connective tissue disordersRheumatoid arthritis✓ Approved
Musculoskeletal and connective tissue disordersJuvenile idiopathic arthritis✓ Approved

Related Research Articles

PubMedThe spine journal : official journal of the North American Spine Society2026-07-18

TNF-α Modulation in Spinal Fusion: High-Dose TNF-α Is Associated With Failed Arthrodesis, While Etanercept Is Associated With Successful Fusion in a Rat Model.

Koerner John D JD, Ng Mitchell K MK, Dalton Jonathan J, Eichbaum Yasmine K YK et al.

TNF-α has been studied in fracture healing; modulation of its activity, either by supraphysiologic exposure or pharmacologic inhibition, may alter the likelihood of pseudarthrosis in spinal fusion. Our main objective is to determine the effects of high- and low-dose tumor necrosis factor-α (TNF-α) and the TNF-α inhibitor Etanercept on spinal fusion outcomes. Laboratory Study METHODS: Seventy-five Wistar rats underwent L4-L5 posterolateral fusion with demineralized bone matrix and received either high-dose TNF-α, low-dose TNF-α, local Etanercept, systemic Etanercept, or carrier alone. At 2, 4, and 28 days, serum and local fusion masses were analyzed with ELISA for IGF-1 and VEGF. Fusion was assessed at 4 weeks by manual palpation and microCT. The study was funded by the ***, no study specific conflicts of interest to report. In vivo, high-dose TNF-α significantly elevated local IGF-1 (22.1 ± 2.1 ng/mg) and VEGF (539 ± 177 pg/mg) at day 2 compared with controls (IGF-1: 6.2 ± 1.2; VEGF: 112 ± 12; P < 0.001). By day 28, only VEGF was reduced in all treatment groups compared with controls (P < 0.001). At 4 weeks, fusion was present in 4/5 controls, 0/5 high-dose TNF-α animals (P = 0.048), 5/5 low-dose TNF-α, 3/5 local Etanercept, and 4/5 systemic Etanercept. MicroCT demonstrated bilateral fusion in 5/5 systemic Etanercept animals, 2/5 controls, and 0/5 high-dose TNF-α (P = 0.016). High-dose TNF-α impaired fusion and was consistently associated with pseudarthrosis despite early increases in growth factor expression. Low-dose TNF-α and Etanercept, administered locally or systemically, did not compromise fusion, with systemic Etanercept showing the highest bilateral fusion rate. These findings indicate that TNF-α modulation significantly influences spinal fusion, and that TNF-α inhibition does not adversely affect arthrodesis. Modulating TNF-α appears to affect fusion success and implementing anti-TNF-α could decrease pseudoarthrosis rates among patients who have elevated TNF-α disease states.

PMID 42468831
Read full article →
PubMedCureus2026-07-17

Incidence and Clinical Characteristics of Herpes Zoster in Patients With Spondyloarthritis Receiving Biologic Therapy: A 36-Month Multicenter Registry-Based Study.

Ben Marzouk Ilham I, Rostom Samira S, El Binoune Imane I, Ghoullam Ghizlane G et al.

Herpes zoster, caused by the reactivation of varicella-zoster virus, has been reported in patients with autoimmune inflammatory diseases receiving biologic therapies. However, data regarding its occurrence in patients with spondyloarthritis (SpA) remain limited. This study aimed to determine the incidence of herpes zoster and describe the clinical characteristics of affected patients with SpA receiving biologic therapy. A multicenter retrospective registry-based study was conducted over a 36-month period, including patients with SpA receiving biologic therapy and registered in the Moroccan Society of Rheumatology Biotherapy Registry (BRMSR). Clinical, laboratory data, including erythrocyte sedimentation rate and C-reactive protein, and therapeutic data were collected at baseline, at 36 months, and at the time of herpes zoster infection. A descriptive statistical analysis was performed. A total of 194 patients with SpA were included, with a mean age of 40.23 ± 13.68 years. The cohort included 123 males (63.4%) and 71 females (36.6%), with a mean disease duration of 11 ± 7 years. Most patients (98.5%) were treated with anti-tumor necrosis factor agents, with etanercept being the most commonly prescribed biologic therapy. The incidence of herpes zoster was 6.87 cases per 1,000 person-years (95% CI: 2.018-16.85). Four cases of herpes zoster were identified. These patients were all older than 55 years, had associated comorbidities, and had prolonged exposure to biologic therapy. The incidence of herpes zoster in patients with SpA receiving biologic therapy was low. The four reported cases shared common clinical characteristics, including older age, the presence of comorbidities, and prolonged exposure to biologic therapy. Further studies with larger populations and longer follow-up are needed to better characterize herpes zoster occurrence in this population.

PMID 42465193
Read full article →
PubMedInternational journal of clinical pharmacy2026-07-17

Budget impact analysis of medication reviews by junior pharmacists in polypharmacy patients: a hospital perspective.

Hectors Toon T, Kooijman Thirza T, van Barreveld Marit M, Kuijvenhoven Marianne M et al.

Pharmacist-led medication reviews are increasingly recognised for generating cost savings within the hospital. However, no cost-analysis has investigated the budget impact of junior pharmacists conducting medication reviews under supervision of clinical pharmacists, nor included recommendations to start-, increase-, or monitor medications. To assess the budget impact of medication reviews by supervised junior pharmacists across hospital wards, explore budget impact differences between drug classes, and identify patient predictors that potentially influence the budget impact. Data of medication reviews were collected over a 19-month period in patients with polypharmacy (≥ 5 medications) who had at least one additional risk factor. We developed a cost model over a one-year horizon, from the hospital perspective. Intervention costs were derived from measured labour time per medication review and salary of junior- and clinical pharmacists. Cost avoidance from potential preventable medication-related readmissions were based on admission time, admission costs and an estimate of preventable medication-related admissions (4.8%). Costs and savings from medication recommendations were aggregated using drug price per daily defined dose and its predicted days of therapy per year, and clustered by drug class. Scenario analyses tested the robustness of medication recommendation savings to account for effectively implemented and additional monitoring recommendations. Patient predictors of budget impact related to medication recommendations were assessed using multivariable linear regression, including age, gender, eGFR, acute admission, medication count, comorbidity, expensive drugs, and ward type. We collected 271 medication reviews, including 1,689 medication recommendations. Per-patient budget impact was negative for the intervention (€104 costs), but positive for medication recommendations (€46 savings), and preventable medication-related readmissions (€239 savings). Total estimated savings were €181 per patient, and €688,000 when upscaled hospital-wide. Opiates, beta receptor agonists, corticosteroids, urological drugs, and muscarine receptor antagonists generated 43% of medication recommendation savings. Erythropoietic growth factors, SGLT2 inhibitors, etanercept, etravirine, and calcium/vitamin D formulations generated 70% of medication recommendation costs. No significant associations were found between any of the included patient characteristics and budget impact related to medication recommendations. Junior pharmacist-led medication reviews provide a modest cost-saving intervention from the hospital perspective, demonstrating savings across clinical populations with polypharmacy.

PMID 42467355
Read full article →
PubMedFrontiers in immunology2026-07-16

Case Report: TRNT1 related autoinflammatory syndrome in a patient with primary ciliary dyskinesia.

Di Gennaro Simona S, Della Casa Francesca F, Petraroli Angelica A, Borrelli Melissa M et al.

We report the case of a young woman with primary ciliary dyskinesia (PCD) who was also diagnosed with tRNA nucleotidyl transferase 1 (TRNT1)-related autoinflammatory syndrome, characterized by recurrent episodes of fever and arthralgia beginning at age 16. To our knowledge, this is the first documented case of homozygosity for the c.1246A>G variant in the TRNT1 gene. The patient had a milder clinical phenotype than previously reported cases with the same variant in a compound heterozygous state. Etanercept administration effectively controlled autoinflammatory manifestations, consistent with prior literature, and no adverse safety events were observed, despite the elevated risk of infectious pulmonary complications due to concurrent PCD. This case underscores the importance of considering autoinflammatory disease in patients presenting with relevant clinical features, even when manifestations are mild or have a delayed onset.

PMID 42459695
Read full article →
PubMedFrontiers in immunology2026-07-16

Successful management of pembrolizumab-associated Stevens-Johnson syndrome/toxic epidermal necrolysis in a patient with uterine serous carcinoma: a case report.

Hamad Tasabeeh T, Serrano Ana Maria AM, Al Kaabi Shaher S, Al Bahri Maiya M et al.

Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare, life-threatening cutaneous adverse reactions associated with immune checkpoint inhibitors (ICIs). Evidence guiding optimal management remains limited. We report the case of a 75-year-old woman with stage IV endometrial carcinoma who developed extensive epidermal necrosis three weeks after the second cycle of maintenance pembrolizumab. Skin biopsy confirmed full-thickness epidermal necrosis, and the SCORTEN score was 3, predicting a high risk of mortality. There was no significant ocular or mucosal involvement. The patient was treated with etanercept, cyclosporine, and pulse methylprednisolone, followed by tapering oral corticosteroids alongside meticulous supportive care. Epidermal detachment stabilized rapidly after therapy and early re-epithelialization occurred within 10 days. The case highlights the importance of early recognition and judicious use of combination immunomodulatory therapy leading to improved outcomes. Multidisciplinary management is essential.

PMID 42459640
Read full article →
PubMedRheumatology and therapy2026-07-14

Long-term Comparative Adherence and Switch Rates in Patients Receiving Advanced Therapies for Rheumatoid Arthritis After Use of One TNF Inhibitor.

Charles-Schoeman Christina C, Oelke Kurt K, Zueger Patrick M PM, Peng Yi Y et al.

Patients with rheumatoid arthritis (RA) often fail to achieve treatment targets with first-line treatment because of poor efficacy or tolerability. However, comparative long-term adherence and switching data among patients initiating a second-line therapy after a first-line tumor necrosis factor inhibitor (TNFi) remain limited. Retrospective data were from the Merative MarketScan® claims database, August 2018-October 2024. Eligible patients were aged ≥ 18 years; diagnosed with RA; initiated upadacitinib (UPA), tofacitinib (TOF), adalimumab (ADA), etanercept (ETA), abatacept (ABA), or tocilizumab (TOC); and had discontinued a first-line TNFi within 12 months prior to index. Treatment adherence and switching outcomes were reported at 1- and 3-year follow-up. Overall, 3782 and 1182 patients were included for the 1- and 3-year analyses, respectively. The proportion of patients with adherence ≥ 80% was highest with UPA at 1-year (49.5%) and 3-year follow-up (35.7%) versus other treatments. Compared with UPA through 3 years, odds of being adherent were significantly lower for TOF (adjusted odds ratio [95% confidence interval]: 0.45 [0.29-0.71]), ADA (0.50 [0.33-0.75]), ETA (0.37 [0.24-0.58]), ABA (0.43 [0.26-0.73]), and TOC (0.46 [0.22-0.99]; p < 0.05). Switch rates were lowest for UPA versus other treatments at 1 year (28.6%) and remained lowest through 3 years (47.6%), while rates for all other treatments increased to approximately 60%. Through 3 years, patients were also significantly (p < 0.05) more likely to switch treatment when receiving TOF (adjusted hazard ratios [95% confidence interval]: 1.40 [1.07-1.84]), ADA (1.44 [1.12-1.86]), ETA (1.57 [1.21-2.03]), ABA (1.56 [1.16-2.10]), and TOC (1.54 [1.03-2.32]) compared with UPA. Median 3-year time to switch was not reached for UPA and was 528-660 days for all other treatments. Among patients with RA who discontinued a first-line TNFi, second-line UPA was associated with significantly greater long-term adherence and lower switching rates than other advanced therapies.

PMID 42446813
Read full article →

+8449 more articles available with a free account

Sign up free to view all articles →

Ask about etanercept